Astressin - RELIEF THERAPEUTICS Holding

Drug Profile

Astressin - RELIEF THERAPEUTICS Holding

Latest Information Update: 04 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator mondoBIOTECH
  • Developer RELIEF THERAPEUTICS Holding
  • Class Antihormones
  • Mechanism of Action Angiogenesis inhibitors; Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Vascular disorders

Most Recent Events

  • 19 Sep 2016 Astressin is available for licensing as of 19 Sep 2016. http://www.relieftherapeutics.com/further-opportunities/
  • 19 Sep 2016 mondoBIOTECH has patent protection for astressin in Japan
  • 18 Jul 2016 THERAMetrics has merged with Relief Therapeutics forming RELIEF THERAPEUTICS Holding
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top